3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Hodgkin Disease
20
Lymphoma
6
Lymphoma, T-Cell, Peripheral
5
Lymphoma, T-Cell
5
Mycosis Fungoides
4
Lymphoma, T-Cell, Cutaneous
4
Lymphomatoid Papulosis
3
Lymphoma, Large-Cell, Anaplastic
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms
2
Lymphoma, Primary Cutaneous Anaplastic Large Cell
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Immunoblastic Lymphadenopathy
2
Hematologic Diseases
2
Enteropathy-Associated T-Cell Lymphoma
2
Squamous Cell Carcinoma of Head and Neck
1
Sezary Syndrome
1
Recurrence
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Mesothelioma, Malignant
1
Melanoma
1
Lymphoma, Extranodal NK-T-Cell
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Leukemia, Large Granular Lymphocytic
1
Leukemia
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
119
Cisplatin
33
lenvatinib
29
Carboplatin
28
Paclitaxel
27
Docetaxel
14
Pemetrexed
13
Fluorouracil
12
Capecitabine
11
Saline Solution
10
Oxaliplatin
10
Gemcitabine
10
Albumin-Bound Paclitaxel
7
olaparib
6
Leucovorin
6
Bevacizumab
6
epacadostat
5
belzutifan
5
Etoposide
5
Cetuximab
5
130-nm albumin-bound paclitaxel
5
trifluridine tipiracil drug combination
3
regorafenib
3
patritumab deruxtecan
3
enzalutamide
3
enfortumab vedotin
3
durvalumab
3
Surgical Procedures, Operative
3
Radiotherapy
3
Levoleucovorin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Brentuximab Vedotin
×
1 year
×
Clear all
NCT02684292
2026-02-18
MK-3475-204
Merck Sharp & Dohme LLC
Phase 3
Completed
304 enrolled
1 FDA